Lanzinger S, Laubner K, Warncke K et al (2024) Clinical characteristics, treatment, and treatment switch after molecular-genetic classification in individuals with maturity-onset diabetes of the young: insights from the multicenter real-world DPV registry
Patients with favorable genetic profiles in GLP-1 and GIP signaling often achieve significant weight loss on tirzepatide monotherapy without additional medications
Call or text 312.312.7873 to book your appointment, or visit our online booking page to schedule a consultation
Semaglutide is administered at a low dose initially, and the dosage is increased gradually according to your bodys tolerance
Many Hashimoto's patients find that moderate doses (0.5-1.0 mg semaglutide, 5-10 mg tirzepatide ) provide meaningful benefits without the gastrointestinal intensity of maximum doses
The primary regulator of ketone body synthesis is fatty acid availability